KIA Medico Private Limited is a recently established pharmaceutical & consumables products wholesaler and distributor. KIA Medico offers branded as well as generic medicines in the field of Neurology, Psychiatry, Cardiology, Gynecology & Obstetrician, Urology, Nephrology, Oncology and Internal Medicine. KIA Medico is striving to become the leading distribution company globally through partnership with multinational and national companies operating in India, who are manufacturing quality and affordable medicines. KIA Medico is headquartered in Mumbai, India with a regional office in Nairobi, Kenya. KIA directors has more than 30 years of experience in the healthcare sector with deep understanding of the various aspects of the healthcare industry. KIA has an employee strength of more than 20 dedicated employees in India and foreign operations. Our team compromises of highly trained personnel and market researchers, who work closely with our approved WHO GMP partner manufacturers to successfully develop products from the earliest conception stage up till product commercialization. At our vendors end, the products are manufactured conforming to internationally accepted standards and adhere to strict regulatory compliance by using supreme quality raw materials and highly advanced technology under the guidance of qualified professionals.

KIA Medico private limited is incorporated under the Indian Companies Act, 2013, with its subsidiary incorporated under Kenyan Companied Act, 2015. KIA Medico has received all the legal documents from the Indian government like Drug license, Import Export license, GST number, Pan Number etc. KIA Medico is currently supplying pharmaceuticals and consumables to different hospitals and charitable institutions across Mumbai. KIA Medico has an extensive presence in Africa with a regional office in Kenya and strong teams in Liberia, Togo, Ghana and other EAC (East African Community) countries. We also have presence in South East countries like Bangladesh and Myanmar. Our distribution strategy is to cover the wide spectrum of pharmaceutical and consumables products which includes government hospitals, military hospitals, private hospitals, private nursing homes, Mission hospitals and NGO/Foundation facilities.

Our key focus market is Kenya mainly driven by increased demand for pharmaceutical drugs in the country. In 2017, pharmaceutical expenditure in Kenya was $ 959 million and is growing at around 10% pa. Achieving universal health coverage is increasingly being prioritised by African governments, which makes President Uhuru Kenyatta’s third key objective as part of the ‘Big Four Agenda’ for 2022. The pharma market is expected to grow at a CAGR of 8% pa in the next five years and reach $ 1.4 billion by 2022.The country's rising population and increasing urbanization, as well as a growing communicable and non-communicable disease burden, are the basis of the forecast. Pharmaceutical imports in Kenya was valued at $ 648 million in 2017, with India accounting for nearly 50% of these imports. The growth of Kenya's generic medicines sector will be driven by increased volume consumption, pushed up by demand together with the support of various government policies aiming to achieve universal healthcare coverage. Generic market was valued at $ 610 million in 2017 consisting of almost 64% of the total market and is expected to grow by 10%.

As a pharmaceutical distributor we lay lot of emphasis on packaging and quality of products from manufacturer to final consumer which are tested for extreme climatic conditions, color coding, special exports cartons, etc. We strive to deliver the product in the same condition to the consumer as it leaves the packaging facility. We also check quality control of our manufacturers through production integrated computer systems, legal specifications and test method with the requirement of European Standard and legal requirements (GMP requirements, marketing authorization). We maintain the stability and shelf life of the pharmaceutical products as specified by FDA. KIA Medico also undertakes comprehensive stability studies in line with ICH guidelines. The promise of our company is in the promise that our work holds for health and life.